PTPI Petros Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—
Margins
Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%
Returns
ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $5.11M |
| Cost of revenue | — | $1.21M |
| Gross profit | — | $3.90M |
| R&D expense | — | $2.62M |
| SG&A expense | $4.64M | $4.63M |
| Operating income | -$4.64M | -$4.63M |
| Interest expense | — | $560,909 |
| Pretax income | -$4.50M | -$705,174 |
| Income tax | $0 | $0 |
| Net income | $1.91M | -$14.32M |
| EBITDA | — | -$1.80M |
| EPS (basic) | -1.56 | -83.47 |
| EPS (diluted) | -1.56 | -83.47 |
| Weighted avg. shares (diluted) | 28.07M | 321,042 |
| Banking | ||
| Net interest income | $256,933 | $371,769 |
| Balance sheet | ||
| Cash & equivalents | $5.14M | $1.72M |
| Receivables | — | $416,076 |
| Inventory | — | $1.35M |
| Current assets | $5.16M | $7.29M |
| PP&E, net | — | $22,948 |
| Intangibles | — | $3.20M |
| Total assets | $5.16M | $10.64M |
| Current liabilities | $2.29M | $18.03M |
| Total liabilities | $2.29M | $18.10M |
| Shareholders' equity | $2.87M | -$7.47M |
| Shares outstanding | 42.28M | 421,124 |
| Cash flow statement | ||
| Operating cash flow | -$6.73M | -$2.60M |
| Capital expenditure | — | $24,587 |
| Free cash flow | — | -$2.63M |
| Investing cash flow | — | -$24,587 |
| Financing cash flow | $8.16M | -$7.00M |
| Depreciation & amortization | — | $2.83M |
| Stock-based compensation | $304,634 | $197,215 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.